Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:59:23 16/07/2024 pm IST			5-day change	1st Jan Change
23.64 ^USD	+1.31%		+12.88%	+10.25%

01/07	Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell Small Cap Comp Value Index	CI
01/07	Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000 Value Index	CI

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

January 11, 2021 at 07:00 pm IST

Denali Therapeutics Inc. announced that Nancy Thornberry has joined the Board of Directors, effective January 8, 2021. Ms. Thornberry is Chief Executive Officer of Kallyope. She was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc.

Latest news about Denali Therapeutics Inc.

Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell Small Cap Comp Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2500 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 2000 Value Index	01/07	CI
Denali Therapeutics Inc.(NasdaqGS:DNLI) added to Russell 3000E Value Index	01/07	CI
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	14/06	CI
Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise	03/06	MT
Denali Therapeutics Inc. Announces FDA Selects DNL126 for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06	CI
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating	08/05	MT
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating	08/05	MT
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial	01/05	CI
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	09/04	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04	MT
Denali Therapeutics Files Prospectus for Secondary Offering	23/03	MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01/03	CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	28/02	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27/02	CI
North American Morning Briefing : S&P 500 Futures -2-	23/02	DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20/02	MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	16/02	DJ
Sanofi: failure of a phase 2 trial against ALS	16/02	CF

Chart Denali Therapeutics Inc.

Duration

Period

More charts

Company Profile

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Denali Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.33 USD

Average target price

38.73 USD

Spread / Average Target

+66.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DENALI THERAPEUTICS INC.	+10.25%	3.33B
VERTEX PHARMACEUTICALS INCORPORATED	+21.66%	127B
REGENERON PHARMACEUTICALS, INC.	+25.02%	117B
ARGENX SE	+26.32%	27.67B
BIONTECH SE	-18.72%	20.33B
GENMAB A/S	-15.43%	16.79B
BEIGENE, LTD.	-17.82%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.93%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.94%	14.43B

Bio Therapeutic Drugs